# A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients

> **NCT05823285** · PHASE1 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QLS31903

## Key facts

- **NCT ID:** NCT05823285
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-22
- **Primary completion:** 2025-06-15
- **Final completion:** 2027-06-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05823285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05823285, "A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05823285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*